SCHEMBL4676747

SCHEMBL4676747

O=C(O)C(O)=CC(=O)c1cc(S(=O)(=O)c2ccc(F)cc2)cs1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
HTT P42858 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CA2 P00918 2/20 0.36
PTGS2 P35354 1/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
AKR1C3 P42330 1/20 0.36
IKBKB O14920 1/20 0.35
HSD11B1 P28845 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HTR2A P28223 4/20 0.33
HTR2C P28335 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676742 1.00 MAPT (0.42) MAPTHTTCYP1A2CYP3A4CYP2D6
SCHEMBL4675379 0.88 HTR6 (0.40) MAPTSMN1; SMN2MEN1KMT2ACA2
SCHEMBL4675381 0.88 HTR6 (0.40) MAPTSMN1; SMN2MEN1KMT2ACA2
SCHEMBL4671766 0.87 ALDH1A1 (0.42) MAPTHTTCYP3A4SMN1; SMN2MEN1
SCHEMBL4671762 0.87 ALDH1A1 (0.42) MAPTHTTCYP3A4SMN1; SMN2MEN1
SCHEMBL4675146 0.83 CFTR (0.38) PTGS2AKR1C2AKR1C1AKR1C3IKBKB
SCHEMBL4675148 0.83 CFTR (0.38) PTGS2AKR1C2AKR1C1AKR1C3IKBKB
SCHEMBL4672596 0.78 PTGS2 (0.38) MAPTKMT2ACA2PTGS2AKR1C2
SCHEMBL4672592 0.78 PTGS2 (0.38) MAPTKMT2ACA2PTGS2AKR1C2
SCHEMBL4674789 0.77 MAPT (0.35) MAPTHTTCYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 MAPT 205/4885HTT 1204/4885CYP1A2 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.